Market Cap 925.20M
Revenue (ttm) 0.00
Net Income (ttm) -89.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 751,200
Avg Vol 239,804
Day's Range N/A - N/A
Shares Out 49.00M
Stochastic %K 35%
Beta 1.03
Analysts Strong Sell
Price Target $38.14

Latest News on ELVN

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 12 days ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF


Enliven's Early Data Stands Out From Peers

Jan 7, 2025, 12:28 AM EST - 3 months ago

Enliven's Early Data Stands Out From Peers


Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 5 months ago

Why Enliven is this analyst's top biotech stock pick


Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 2 years ago

Imara Announces Stockholder Approval of Merger With Enliven


Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 2 years ago

Enliven Therapeutics and Imara Announce Merger Agreement


Imara: Potential Liquidation

Sep 29, 2022, 3:06 PM EDT - 2 years ago

Imara: Potential Liquidation


Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 3 years ago

Read Why Imara Shares Are Falling Today


Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 3 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients


Imara to Participate in Upcoming Investor Conferences

Sep 15, 2021, 7:00 AM EDT - 3 years ago

Imara to Participate in Upcoming Investor Conferences


Imara to Present at Upcoming Investor Conferences

Sep 3, 2021, 7:00 AM EDT - 3 years ago

Imara to Present at Upcoming Investor Conferences